Search results
ASLAN expands research on atopic dermatitis treatment By Investing.com
Investing.com· 2 days agoASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage biopharmaceutical company, has announced a new...
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks· 2 days agoAlthough the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 15 hours agoKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript May 3, 2024 Kymera...
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 17 hours agoKymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the...
Earnings call: Kymera Therapeutics reports progress in drug development By Investing.com
Investing.com· 20 hours agoKymera Therapeutics, during their first quarter 2024 earnings call, provided a comprehensive update...
11 Oversold Growth Stocks to Buy Right Now
Insider Monkey via Yahoo Finance· 5 days agoIn this article, we will take a look at the 11 oversold growth stocks to buy right now. To skip our analysis of the recent trends and market activity,...
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Zacks via Yahoo Finance· 5 days agoEvaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoFirst quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first